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Abstract
Background: In a complex disease, the expression of many genes can be significantly altered, leading to the
appearance of a differentially expressed “disease module”. Some of these genes directly correspond to the disease
phenotype, (i.e. “driver” genes), while others represent closely-related first-degree neighbours in gene interaction
space. The remaining genes consist of further removed “passenger” genes, which are often not directly related to
the original cause of the disease. For prognostic and diagnostic purposes, it is crucial to be able to separate the
group of “driver” genes and their first-degree neighbours, (i.e. “core module”) from the general “disease module”.
Results: We have developed COMBINER: COre Module Biomarker Identification with Network ExploRation.
COMBINER is a novel pathway-based approach for selecting highly reproducible discriminative biomarkers. We
applied COMBINER to three benchmark breast cancer datasets for identifying prognostic biomarkers. COMBINER-
derived biomarkers exhibited 10-fold higher reproducibility than other methods, with up to 30-fold greater
enrichment for known cancer-related genes, and 4-fold enrichment for known breast cancer susceptible genes.
More than 50% and 40% of the resulting biomarkers were cancer and breast cancer specific, respectively. The
identified modules were overlaid onto a map of intracellular pathways that comprehensively highlighted the
hallmarks of cancer. Furthermore, we constructed a global regulatory network intertwining several functional
clusters and uncovered 13 confident “driver” genes of breast cancer metastasis.
Conclusions: COMBINER can efficiently and robustly identify disease core module genes and construct their
associated regulatory network. In the same way, it is potentially applicable in the characterization of any disease
that can be probed with microarrays.
Background
In recent years, gene expression signatures based on
DNA microarray technology have proven useful for pre-
dicting the risk of breast cancer. Agendia’sM a m m a P r i n t
has become the first FDA-cleared breast cancer prognosis
marker chip containing 70 gene signatures [1]. Many
other microarray-based biomarkers, such as 76 gene
signatures [2] have been derived using independent data
sources. However, there are only three overlaps between
MammaPrint’s 70-gene and Wang’s 76-gene signatures.
Furthermore, many of these markers are functionally
unrelated to breast cancer. In order to identify robust,
functionally relevant disease biomarkers, it is crucial to
find gene signatures that are consistent in various data
sources.
A complex disease such as breast cancer results in many
differentially expressed genes (DEGs), which together can
be used to construct a “disease module” network [3].
Some of these DEGs directly correspond to the disease
phenotype (i.e. “driver” genes). The expression changes
enacted on the driver genes lead to a cascade of changes
of other genes: initially to their first-degree interaction
neighbors [4], followed by downstream effects to so-called
“passenger” genes. Due to their direct relevance to the
biology of the disease in question, the expression changes
of the driver genes and their first-degree neighbours (i.e.
members of the “core module”), should be more consis-
tent than those of the passenger genes when compared
across independent cohorts. However, it is often difficult
to separate the core module from the passenger genes for
a given disease [5,6]. In this paper, we aim to isolate the
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further identify the driver genes using network analysis.
The most intuitive way of finding the disease core mod-
ule is to identify the Differential Expressed Genes (DEGs)
over various cohorts. Unfortunately, the typically larger
number of passenger genes in each cohort will contribute
to the majority of gene overlaps, due to statistical chance.
A more biologically-motivated technique for identifying
t h ec o r em o d u l ei st of i n do v e rlapping differentially
expressed pathways. However, a pathway may also contain
hundreds of genes with respect to the disease in question,
while only a functional submodule (a small group of
genes) is differentially expressed. These submodules are
often overlooked in pathway enrichment analysis.
In light of the aforementioned challenges, we propose to
identify Pathway Activities (PAs) from cohorts of data and
use supervised classification to isolate a consistent core
module. Each PA is a vector aggregating the information
of a few genes expressed in a pathway [7,8]. The use of
PAs for biomarker identification has been shown improve
reproducibility and disease-related functional enrichment
of the resulting biomarkers [7]. The main idea behind our
method is to infer the most significant PAs in each data
cohort, and validate these PAs using classification methods
in other cohorts. If a PA also scores highly in all the other
cohorts, we consider it to be consistently differentially
expressed in the disease of interest. Furthermore, we
would consider the genes that make up the PA to belong
to the disease core module.
In this work, we develop a novel biomarker identifica-
tion framework entitled COre Module Biomarker Identi-
fication with Network ExploRation (COMBINER).
COMBINER identifies “core module” (Figure 1) that are
consistently differentially expressed as a whole in the
data cohorts of interest. COMBINER uses a Core Module
Inference (CMI) component to infer candidate PAs from
pathway database, a Consensus Feature Elimination
(CFE) component to filter out irreproducible PAs, and a
multi-level reproducibility validation framework to find
the consistent PAs, which in turn make up the complete
core module. In its final step, COMBINER uses known
pathways and protein networks to identify the driver
genes within this core module.
To illustrate its utility, we apply COMBINER to three
benchmark breast cancer datasets. We evaluate the
resulting core module for accuracy, reproducibility, and
enrichment for known cancer-related genes. We then
explore the roles of the COMBINER-identified core
module in the hallmarks of cancer, and we reconstruct a
breast cancer-specific interaction network composed of
functionally coherent modules. Finally, we summarize
our analyses by identifying 13 high confidence driver
genes from COMBINER markers.
Results and Discussion
Overview
COMBINER is a multi-level optimization framework for
identifying core module markers (Figure 1 and Meth-
o d s ) .B r i e f l y ,C O M B I N E Ri n f ers candidate submodules
from known pathways, identifies the reproducible “core
module” using independent cohorts, and uses intracellu-
lar signaling pathways and protein networks to identify
the “driver” genes from the “core module”.
We applied COMBINER to three independent breast
cancer datasets to evaluate its effectiveness: Netherlands
[9], USA [2], and Belgium [10]. We obtained pathway
information from the MsigDB v3.0 Canonical Pathways
subset [11]. To decrease redundancy, we applied path-
way filtering to remove bulky pathways such as KEGG
Pathways of Cancer. This resulted in a pathway dataset
containing 624 pathways with 5,155 genes assayed in all
three benchmark datasets.
Core Module Inference improves reproducibility and
classification accuracy
A primary challenge of pathway inference is to find path-
way subsets that are reproducible between independent
datasets. We compared Core Module Inference (CMI)
with five other inference methods as well as individual
genes (see Methods). When compared to a range of num-
bers of inferred Pathway Activities (PAs), CMI showed
two-fold increased reproducibility over the related CORG
method and about a 10-fold improvement over other
methods (Figure 2).
We then compared the classification accuracy of CMI
and the other inference methods using Linear Discrimi-
nant Analysis-Consensus Feature Elimination (LDA-CFE)
classifiers focused on the top 100 inferred PAs (Methods).
As shown in Figure 3, COMBINER run using PA vectors
identified by CMI (CMI-COMBINER) exhibits better
overall accuracy than the other methods coupled with
COMBINER. Similarly, CMI also shows good overall accu-
racy using the SVM classifier (Additional file 1, Figure S1).
Core module markers enrich cancer-related genes
We compared the enrichment of known cancer genes in
the biomarkers discoveredb yC M I - C O M B I N E R ,( 9 3
genes); CORG-COMBINER, (i.e. COMBINER run using
CORG activity vectors), (123 genes); Subnetwork markers
(1162 genes) ( [7], http://www.cellcircuits.com); Mamma-
Print’s 70-gene signature (G70) (70 genes) [1]; and Wang’s
76-gene signature (G76) (76 genes) [2]. Seven known can-
cer gene datasets were compared (see Materials and meth-
ods). Both CMI-COMBINER and CORG-COMBINER
showed much higher enrichment of cancer-related genes
in their biomarker signatures (Table 1). Specifically, CMI-
and CORG-COMBINER showed up to 4-fold increased
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Page 2 of 11Figure 1 Schematic overview of COMBINER. COMBINER uses Core Module Inference (CMI) to infer candidate pathway activities from each
pathway in an inference dataset, Consensus Feature Elimination (CFE) to filter out irreproducible activities in validation datasets, and a multi-level
reproducibility validation framework to conduct pair-wise validations to find common reproducible activities which make up the “core module”.
To identify the driver genes, we reassemble the resulting core module markers in both intracellular signalling pathways and a large overall
regulatory network reflecting interactions between pathways.
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Page 3 of 11enrichment over subnetwork markers and up to 30-fold
enrichment over other gene signatures. In particular for
known breast cancer genes in Census, they exhibited up to
4 fold enrichment over others. More than 50% and 40% of
the resulting biomarkers are cancer and breast cancer spe-
cific, respectively. Additionally, CMI-COMBINER showed
greater enrichment than CORG-COMBINER with respect
to the Atlas of Cancer Genes, which is the largest cancer
gene collection. Consistent to Chuang et al’s results [7],.
we also found insignificant enrichment in CANgene data-
set including 122 mutative genes from 11 breast cancer
cell lines. A possible explanation is that “the cancer cell
lines capture a different disease state than that found in
the population of patients surveyed by microarray profil-
ing.” [7] The COMBINER core module markers with asso-
ciated pathways are summarized in Additional file 2, Table
S1 and Additional file 3, Table S2. Additional file 4, Table
S3 lists the overlaps between CMI-/CORG-COMBINER
and KEGG pathways of cancer, along with up-/down-
regulation information.
Core module markers highlight the hallmarks of cancer
As shown in Figure 4, the COMBINER-discovered bio-
markers are overlaid on the hallmarks of cancer [12,13],
which integrate the common intracellular signalling path-
ways of all subtypes of cancer. The components of the
core module markers from CMI and CORG along with
eighteen common markers are listed in different fonts.
The remaining proteins (most were not differentially
expressed) in the pathways are consolidated into unlabeled
nodes. Figure 4 shows that the identified core module
genes comprehensively highlight the hallmarks, demon-
strating the high specificity of COMBINER. In particular,
18 common markers, which we regard as the most reliable
predictors, describe well-characterized processes involving
growth factors, survival factors, the cell cycle, and the
ExtraCellular Matrix (ECM). The modules unique to
CMI-COMBINER include anti-apoptosis and JAK-STAT
cascades, while pathways describing anti-growth factors
and death factors were unique to CORG-COMBINER. A
few well-known mutant proteins, including cyclin D1 and
p53, may play an important role in connecting other sig-
natures [7], but they showed only limited predictive ability
in the three breast cancer datasets.
Core module markers in predicted protein-protein
interaction networks underpin functional modules
Figure 5 shows how a regulatory network was con-
structed using the interactome of the core module mar-
kers. The regulatory network was divided into a few
functional modules, including cell cycle and ECM. These
functional modules were interconnected by 20 “hub”
Figure 2 Reproducible power of pathway inference methods. The reproducibility power of a pathway inference method in an inference-
validation pair datasets is measured by Cscore(N)=
1
N
 N
i=1 tscore(Pi
I) · tscore(Pi
V), where Pi
I is the i
th PA in descending order in the
inference dataset, Pi
V is its corresponding PA in the validation dataset, and N is the number of selected inferred pathways. The overall
reproducibility is then defined as the average Cscore of selected top inferred pathway activities over all six inference-validation pairs. We
compared CMI with five inference methods, including the CORG, mean, median, first component score of PCA, as well as no-inferring gene
method. Comparing by different ranges of top inferred activities, the CMI showed significant better overall reproducibility over other methods.
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Page 4 of 11genes (larger pink/green nodes), 13 of which overlapped
with the common marker genes (Additional file 2, Table
S1). Our results imply that these 13 “hub” markers are
the essential “driver” genes of breast cancer metastasis
(Table 2). For example, BRCA1 is among the most well-
characterized genes whose mutation gives rise to breast
cancer. In addition, low E2F1 transcript levels strongly
p r e d i c t e dg o o dp r o g n o s i sb a s e do nq u a n t i t a t i v eR T - P C R
in 317 primary breast cancer patients [14]. We further
enlarged the nodes of three standard breast cancer indi-
cators TP53, BRCA1, and ERBB2, which connect many
of the surrounding hub genes. Although TP53 and
Figure 3 Comparison of CMI and other inference methods-based COMBINER using LDA-CFE classifiers focused on the top 100 inferred
pathways. Seven methods were compared here, including CMI, CORG, Mean, Median, PCA, LLR and Individual Gene. (a) Classification accuracy
for best feature set: pair-wise comparisons. Starting from all 100 inferred pathway activities, we recursively removed the activity with the lowest
average weight from 500 LDA classifiers, until the maximum average AUC was reached. The process was repeated 100 times and the most
frequently occurring marker set was regarded as the ultimate marker. We measured classification accuracy of each method by computing AUC
mean ± standard error for the final feature set. (b) Classification accuracy overall. The overall classification accuracy was measured by computing
the average maximum mean AUC of all six inference-validation pairs. On average, CMI was superior to the other methods, even though its
activity vector consisted of expression values from only a few genes in each pathway.
Table 1 Cancer Gene Enrichment rate of various breast
cancer gene signatures
CMI-
COMBINER
CORG-
COMBINER
Subnetwork G70 G76
NetPath 54.17%* 50.41%* 26.33%* 10.00% 10.53%
Atlas 60.42%* 46.34% 32.87% 15.71% 18.42%
Census 11.46%* 13.82%* 5.42%* 2.86% 0.00%
CANgene 1.04% 1.63% 0.52% 0.00% 0.00%
G2SBC 43.75%* 46.34%* 19.02% 21.43% 10.53%
COSMIC 16.67% 17.89%* 7.06% 4.29% 1.32%
KEGG 35.42%* 29.27%* 9.90%* 8.57% 1.32%
* p-value < 0.05 for hypergeometric tests
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Page 5 of 11ERBB2 are useful for a mechanistic understanding of
breast cancer, they were not identified as discriminative
gene markers. A regulatory network was also created
representing CORG-COMBINER (Additional file 5, Fig-
ure S2), but no additional “hub” markers were found.
Conclusions
Identifying accurate and reproducible disease biomarkers
is an important challenge for gene expression analysis.
To facilitate this task, we developed COMBINER, a
novel pathway-based biomarker identification method
that extracts the essential “core module” of disease from
known biological networks. Compared to existing meth-
ods, COMBINER substantially improves the reproduci-
bility and cancer-specific enrichment of its resulting
biomarkers. We examined the identified markers in
intracellular signalling networks highlighting the
hallmarks of cancer. Reassembling the core module
genes into a regulatory network, we found 13 “driver”
genes connecting eight functional modules. We antici-
pate such molecular descriptions to prove even more
useful when applied to diseases that are less well-charac-
terized; our current work focuses on several such
applications.
Methods
Gene expression, pathways, cancer gene databases, and
interactome
We used three breast cancer datasets from different coun-
tries of origin to evaluate our method: Netherlands [9],
USA [2], and Belgium [10]. Each dataset recorded whether
the assayed patients developed metastasis within 5 years
after surgery. The Netherlands, USA, and Belgium datasets
contain expression profiles for 295, 286, and 198 patients,
Figure 4 COMBINER biomarkers overlap with well-known cancer-related signalling pathways. The core module markers from CMI and
CORG are listed in normal and italic fonts, respectively, while the common markers are in bold. Red/green color denotes up-/down-regulation.
The remaining proteins in the circuit are abstracted as unlabeled nodes. The common core module markers of CMI- and CORG-COMBINER
describe growth factors, survival factors, the cell cycle, and the extracellular matrix. Unique pathways to CMI-COMBINER include the anti-
apoptosis and JAK-STAT cascade, while anti-growth factor and death factor pathways were discovered uniquely by CORG-COMBINER.
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Page 6 of 11respectively, with 78, 107, and 35 patients experiencing
metastasis. All of the patients in the USA and Belgium
datasets had lymph-node-negative disease, although their
estrogen receptor (ER) types differed. The Netherlands
data contained both lymph-node positive and negative
disease patients with differing ER types, 130 of which
received adjuvant systemic therapy including chemother-
apy and hormonal therapy. We performed a two-tailed
t-test on the gene expression values of each dataset to dis-
tinguish between metastatic and non-metastatic patients,
Figure 5 Regulatory networks of CMI-COMBINER biomarkers The pink/green nodes denote up-/down-regulation of gene expression.
The orange nodes indicate contradictory regulation in different datasets. Larger nodes are highly connected in the network; most are overlaps
between CMI- and CORG-COMBINER. The three well-known oncogenes for breast cancer metastasis-TP53, BRCA1, and ERBB2-were enlarged
further. The core module markers were reassembled into an overall interaction network. Known functional modules neatly overlay well-
connected clusters. Many of the highly connected genes are known “driver” genes playing an important role in breast cancer metastasis.
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Page 7 of 11considering genes with p-value ≤.05 as differentially
expressed (DE).
The reference cancer genes for enrichment analysis were
collected from datasets including NetPath [15] (all cancers,
http://www.netpath.org/), Atlas of Cancer Genes [16] (all
cancers, http://atlasgeneticsoncology.org/), Census Genes
[17] (all cancers), CANgenes [18] (breast cancer), G2SBC
[19] (breast cancer, http://www.itb.cnr.it/breastcancer/),
and KEGG Pathways of Cancer [20] (all cancers, KEGG
hsa05200 http://www.genome.jp/kegg/pathway/hsa/
hsa05200.html).
Pathway information was obtained from the MsigDB
v3.0 Canonical Pathways subset [11,21]. This collection
contains 880 pathways collected from seven hand-
curated pathway databases including KEGG, Reactome,
and Biocarta.
Predicted protein protein interaction information was
obtained from STRING 9 [22].
Core Module Inference
The CMI method adopts the strategy of the CORG
method [8] of finding the genes with the most discrimi-
native power, differing in three ways: first, the CORG
method collects CORGs only from the up- or downre-
gulated subset of genes in a pathway, and some key
genes can thus be discarded. In contrast, CMI considers
both up- and downregulation together. Second, CMI
improves the greedy search for the discriminative set of
genes. Third, CMI considers only differentially expressed
genes. As illustrated in Figure 1, given a pathway con-
sisting of genes {g1,... gi, ..., gn} ranking by a descending
order of their absolute t-scores, with their normalized
expression values {z(g1),..., z(gn)}, determining a core
module {g1,..., gK} is equivalent to finding the K
th com-
ponent, such that
K =a r gm a x (tscore(Pj)), (1)
where
Pj =
⎧
⎪ ⎨
⎪ ⎩
 j
i=1 z(gi)sign(tscore(gi))
 
j
,1≤ j ≤ min(|gi ∈ DEGs|,20),|gi ∈ DEGs| > 0,
0, |gi ∈ DEGs| =0 .
(2)
gi is the i
th DEG in descending order and Pj is the PA
containing from g1 to gj.|gi Î DEGs | denotes number
of DEGs in the pathway. The DEGs by default are the
genes with p-value ≤ 0.05 in a two-tailed t-test. We
l i m i tt h el a r g e s tm a r k e rs i z et o2 0D E G s .I nf a c t ,a l l
marker sets have fewer than 20 components.
Reproducibility power
We consider an inference-validation pair datasets to be
reproducible if their pathway activities provide similar
discriminative power. First, we rank the PAs inferred
from the inference dataset in descending order by their
tscores. Then, we define reproducibility by
Cscore(N)=
1
N
 N
i=1 tscore(Pi
I) · tscore(Pi
V), (3)
where Pi
I is the i
th PA in descending order in the
inference dataset, and Pi
V is its corresponding PA in the
validation dataset. For the breast cancer datasets, the
overall reproducibility is then given by the average
Cscore of the inferred pathways over all six inference-
validation pairs.
Six methods were compared in this work, including
CMI, CORG [8], Mean [23], Median [23], PCA [24], and
Individual Gene. LLR(Log likelihood Ratio, [25]) was not
compared here, because it is not discussed in the same
gene expression space.
Consensus Feature Elimination (CFE)
In this work, gene expression and activity vectors are
generalized as features for classification. Given a set of
features {x 1, x2,..., xn} with class labels {y1, y2,..., yn} Î
Table 2 Confident “driver” genes for breast cancer metastasis
Symbol Entrez Description
MAP2K1 [32] 5604 mitogen-activated protein kinase kinase 1
E2F1 [14] 1869 E2F transcription factor 1
GRB2 [33] 2885 growth factor receptor-bound protein 2
NFKB1 [34] 4790 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
RB1 [35] 5925 retinoblastoma 1
BRCA1 [36] 672 breast cancer 1, early onset
FOS [37] 2353 v-fos FBJ murine osteosarcoma viral oncogene homolog
SOS1 [38] 6654 son of sevenless homolog 1 (Drosophila)
PIK3CA [39] 5290 phosphoinositide-3-kinase, catalytic, alpha polypeptide
JAK1 [40] 3716 Janus kinase 1
SHC1 [41] 6464 SHC (Src homology 2 domain containing) transforming protein 1
MYC [42] 4609 v-myc myelocytomatosis viral oncogene homolog (avian)
CCNA2 [37] 890 cyclin A2
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Page 8 of 11{-1, +1}, the task of binary classification is to find a deci-
sion function
D(x)
⎧
⎪ ⎨
⎪ ⎩
> 0 ⇒ x ∈ class(+)
< 0 ⇒ x ∈ class(−)
=0⇒ x ∈ decision boundary,
(4)
We choose a linear decision function, which can be
described as a separating hyperplane:
D(x) = w · x + b, (5)
with w the weight vector and b the bias value.
Linear classifiers such as Linear Discriminant Analysis
(LDA) [26] and linear Support Vector Machines (SVM)
[27] use differing optimization criteria to estimate the
weight vector. Intuitively, the weights indicate the
importance of the associated features. Guyon et al pro-
posed Recursive Feature Elimination (RFE), which
removes features recursively based on their weights [28].
However, classical RFE exhibits lack of stability in fea-
ture selection [29]. In contrast to binary classification
tasks that emphasize maximization of classification
accuracy, biomarker identification requires features that
are both accurate and reproducible across multiple
experiments. Thus, we propose a Consensus Feature
Elimination (CFE) approach to improve the stability of
RFE. As illustrated in Figure 6, we first generate 100
alternative 5-fold random splits of samples, upon which
we construct 500 classifiers and record their AUCs
(Area Under Receiver Operating Characteristic Curves)
and weight vectors. Each feature was then ranked by
average square weight ¯ w =
 500
j=1 (wj)
2/500.T h el o w e s t
ranking feature was removed recursively until the maxi-
mum average AUC was achieved. This process, which
has also been called Multiple RFE [30] or ensemble fea-
ture selection [31] is known to increase biomarker
reproducibility and accuracy by as much as 30% and
15%, respectively. For the breast cancer datasets
described in this work, we found the maximum AUC to
be very stable, while the corresponding biomarker set
was not always unique. Thus we chose to repeat the
above procedure 100 times, selecting the most fre-
quently occurring biomarkers as the final marker set.
Seven methods were compared in this work, including
CMI, CORG [8], Mean [23], Median [23], PCA [24],
LLR [25], and Individual Gene.
Cancer gene enrichment analysis
The cancer gene enrichment analysis examines over-
representation of known cancer genes in a gene signa-
ture. Assuming the total number of genes N, cancer
genes M, and signature genes J, the probability of having
more than K cancer genes in a signature follows a
hypergeometric distribution:
P(#of cancer genes > K)=1−
 K
i=0
 
J
i
  
N−J
M−i
 
 N
M
  . (6)
Software
COMBINER was implemented in Matlab R2010a with
Bioinformatics toolbox v3.5. The source code is available
on http://www.ruotingyang.com.
Additional material
Additional file 1: Figure S1: Comparison of CMI and other pathway
inference methods using SVM-CFE classifiers subject to top 100
inferred pathways.
Figure 6 Diagram of Consensus Feature Elimination.W ef i r s t
generated 100 alternative 5-fold random splits of samples, upon
which it constructs 500 classifiers with their AUCs as well as weight
vectors. Each feature is then ranked by its average square weight.
The lowest ranking feature was removed backward until the
maximum average AUC was achieved. The procedure is repeated
for 100 times, and the most frequently occurring marker set was
regarded to be the ultimate marker.
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Page 9 of 11Additional file 2: Table S1: List of core module genes identified by
CMI and CORG.
Additional file 3: Table S2: Pathway markers identified by all
methods.
Additional file 4: Table S3: List of core module genes overlaid in
KEGG pathway of cancers.
Additional file 5: Figure S2: Unique core module of cancer pathway
identified by CORG-COMBINER method.
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